Regeneron Pharmaceuticals (REGN) Interest Expenses (2009 - 2026)

Regeneron Pharmaceuticals' Interest Expenses history runs 17 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 48.28% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $48.0 million (changed 0.42% YoY), while the FY2025 annual figure was $43.8 million, down 20.65% from the prior year.
• Interest Expenses was $12.9 million for Q1 2026 at Regeneron Pharmaceuticals, up from $12.2 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $19.3 million in Q3 2025 to a low of $3.6 million in Q2 2025.
• Historically, Interest Expenses has averaged $14.4 million across 5 years, with a median of $14.8 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Interest Expenses slumped 75.68% in 2025, then jumped 48.28% in 2026.
• A 5-year view of Interest Expenses shows it stood at $17.4 million in 2022, then grew by 5.17% to $18.3 million in 2023, then slumped by 42.62% to $10.5 million in 2024, then rose by 16.19% to $12.2 million in 2025, then grew by 5.74% to $12.9 million in 2026.
• The last three Interest Expenses figures came in at $12.9 million (Q1 2026), $12.2 million (Q4 2025), and $19.3 million (Q3 2025), per Business Quant data.